CROCETTA, VALENTINA
 Distribuzione geografica
Continente #
NA - Nord America 905
EU - Europa 561
AS - Asia 172
Continente sconosciuto - Info sul continente non disponibili 4
SA - Sud America 2
AF - Africa 1
Totale 1.645
Nazione #
US - Stati Uniti d'America 902
IT - Italia 133
IE - Irlanda 125
SE - Svezia 114
CN - Cina 107
GB - Regno Unito 55
UA - Ucraina 53
TR - Turchia 40
FR - Francia 27
DE - Germania 25
VN - Vietnam 13
FI - Finlandia 11
IN - India 7
CH - Svizzera 4
EU - Europa 4
PL - Polonia 3
BD - Bangladesh 2
BE - Belgio 2
BG - Bulgaria 2
RS - Serbia 2
SG - Singapore 2
BR - Brasile 1
CA - Canada 1
CZ - Repubblica Ceca 1
LU - Lussemburgo 1
MK - Macedonia 1
MY - Malesia 1
NL - Olanda 1
PA - Panama 1
PR - Porto Rico 1
PY - Paraguay 1
RU - Federazione Russa 1
SC - Seychelles 1
Totale 1.645
Città #
Chandler 269
Dublin 124
Jacksonville 108
Ashburn 93
Chieti 62
Princeton 58
Southend 42
Dearborn 39
Ann Arbor 28
Nanjing 26
Wilmington 26
Beijing 25
Izmir 23
Washington 18
Dong Ket 13
Altamura 12
Cambridge 12
Nanchang 9
Jiaxing 8
Kunming 8
Varallo 8
Vittuone 7
Norwalk 6
Rome 6
Woodbridge 6
Boardman 5
Monfalcone 5
Shenyang 5
Geneva 4
Tianjin 4
Changsha 3
Civitanova Marche 3
Edinburgh 3
Falls Church 3
Hefei 3
Shanghai 3
Ankara 2
Belgrade 2
Brussels 2
Chicago 2
Delhi 2
Grevenbroich 2
Hebei 2
Lanzhou 2
Las Vegas 2
Molise 2
Napoli 2
New Delhi 2
Ningbo 2
Sofia 2
Warsaw 2
Amsterdam 1
Asunción 1
Augusta 1
Chaoyang 1
Dallas 1
Florence 1
Frankfurt am Main 1
Guangzhou 1
Hangzhou 1
Hanover 1
Helsinki 1
Houston 1
Jinan 1
Kuala Lumpur 1
Limana 1
London 1
Los Angeles 1
Luxembourg 1
Manchester 1
Messina 1
Montreal 1
Oderzo 1
Orange 1
Orsogna 1
Panama City 1
Paris 1
Rzeszów 1
Saint Louis 1
San Juan 1
San Mateo 1
St Louis 1
São Paulo 1
Teramo 1
Trento 1
Udine 1
Villamagna 1
Totale 1.143
Nome #
Fatal sepsis by Klebsiella pneumoniae in a patient with systemic lupus erythematosus: the importance of postmortem microbiological examination for the ex post diagnosis of infection. 113
Cooperative pathogenicity in cystic fibrosis: Stenotrophomonas maltophilia modulates Pseudomonas aeruginosa virulence in mixed biofilm 94
Phylogenetic relationships, biofilm formation, motility, antibiotic resistance and extended virulence genotypes among Escherichia coli strains from women with community-onset primitive acute pyelonephritis 89
In vitro and in vivo evaluation of BMAP-derived peptides for the treatment of cystic fibrosis-related pulmonary infections 75
In vitro activity of levofloxacin against planktonic and biofilm Stenotrophomonas maltophilia lifestyles under conditions relevant to pulmonary infection in cystic fibrosis, and relationship with SmeDEF multidrug efflux pump expression 75
Stenotrophomonas maltophilia Phenotypic and Genotypic Diversity during a 10-year Colonization in the Lungs of a Cystic Fibrosis Patient 74
Evaluation of antibacterial and antibiofilm mechanisms by usnic acid against methicillin-resistant Staphylococcus aureus 72
Evolution of Stenotrophomonas maltophilia in Cystic Fibrosis Lung over Chronic Infection: A Genomic and Phenotypic Population Study 72
Stenotrophomonas maltophilia virulence and specific variations in trace elements during acute lung infection: implications in cystic fibrosis. 69
Exposure to extremely low-frequency magnetic field affects biofilm formation by cystic fibrosis pathogens 68
Stenotrophomonas maltophilia mutant lacking flagella remains virulent in DBA/2N mice but is less efficient in stimulating TNF-α expression 65
In vitro activity of colistin against biofilm by Pseudomonas aeruginosa is significantly improved under "cystic fibrosis-like" physicochemical conditions 62
New insights in Staphylococcus pseudintermedius pathogenicity: Antibiotic-resistant biofilm formation by a human wound-associated strain 61
Effect of levofloxacin on Stenotrophomonas maltophilia biofilm and its relationship with SmeDEF multidrug efflux pump expression under conditions relevant to the cystic fibrosis lung 54
Characterization of biofilm formation by Myroides odoratimimus isolated from post-traumatic calcaneal recurrent ulcer in diabetic patient 54
Identification, antimicrobial resistance and molecular characterization of the human emerging pathogen Streptococcus gallolyticus subsp pasteurianus 54
In vitro and in vivo evaluation of BMAP-derived peptides for the treatment of cystic fibrosis-related pulmonary infections 53
Microbial cooperation in cystic fibrosis: Stenotrophomonas maltophilia significantly modulates Pseudomonas aeruginosa virulence. 51
Stenotrophomonas maltophilia phenotypic and genotypic diversity during a 10-year infection in the lungs of a cystic fibrosis patient 51
Modulation of biofilm formation by Stenotrophomonas maltophilia during chronic lung infection in cystic fibrosis patients: a longitudinal population study 51
New insights in Staphylococcus pseudintermedius pathogenicity: antibiotic-resistant biofilm formed by a human wound-associated strain. 50
“Indirect pathogenicity” in cystic fibrosis during pulmonary exacerbations: Stenotrophomonas maltophilia modulates Pseudomonas aeruginosa virulence in a Galleria mellonella model. 44
Individuation and evaluation of new bacteriophages for the treatment of cystic fibrosis biofilm-related lung infections caused by Pseudomonas aeruginosa. 44
The importance of postmortem microbiological examination for the ex post diagnosis of infection: fatal sepsis by Klebsiella pneumoniae in a patient with systemic lupus erythematosus. 41
Efficacy of phages and antibiotic-phage combinations against biofilm by Pseudomonas aeruginosa from cystic fibrosis patients 40
Toward optimization of antimicrobial peptides for the treatment of multidrug resistant infections in cystic fibrosis. 38
Individuation and evaluation of new bacteriophages for the treatment of cystic fibrosis lung infection caused by Pseudomonas aeruginosa 38
In vivo bacterial cooperation in cystic fibrosis: exposure to Stenotrophomonas maltophilia affects Pseudomonas aeruginosa virulence in murine model of acute lung infection. 38
Potential Novel Therapeutic Strategies in Cystic Fibrosis: Antimicrobial and Anti-Biofilm Activity of Natural and Designed Alpha-Helical Peptides against Staphylococcus aureus, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia. 34
In Vitro Newly Isolated Environmental Phage Activity against Biofilms Preformed by Pseudomonas aeruginosa from Patients with Cystic Fibrosis 33
Toward optimization of a BMAP-derived antimicrobial peptide for the treatment of pulmonary infections caused by Pseudomonas aeruginosa in cystic fibrosis patients. 29
A longitudinal population genomic study of Stenotrophomonas maltophilia in cystic fibrosis patients: expanding our knowledge about an emerging opportunistic pathogen. 17
Totale 1.803
Categoria #
all - tutte 6.061
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.061


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201934 0 0 0 0 0 0 0 0 0 2 4 28
2019/2020251 57 12 4 2 30 25 32 20 6 20 41 2
2020/2021196 22 10 53 8 15 33 2 4 7 15 7 20
2021/2022207 1 11 3 49 4 2 2 14 12 1 36 72
2022/2023592 47 85 54 77 40 106 30 43 75 5 23 7
2023/2024235 11 12 32 18 23 81 38 19 1 0 0 0
Totale 1.803